DUQUE AFONSO, Jesús, FINKE, Jürgen, NGOYA, Maud, GALIMARD, Jacques-Emmanuel, CRADDOCK, Charles, RAJ, Kavita, BLOOR, Adrian, NICHOLSON, Emma, EDER, Matthias, ORCHARD, Kim, VALERIUS, Thomas, SNOWDEN, John A., THOLOULI, Eleni, CRAWLEY, Charles, COLLIN, Matthew P., WILSON, Keith M. O., GADISSEUR, Alain, PROTHEROE, Rachel, WAGNER-DROUET, Eva-Maria, SAVANI, Bipin N., SPYRIDONIDIS, Alexandros, CICERI, Fabio, NAGLER, Arnon und MOHTY, Mohamad, 2023. Comparison of fludarabine/melphalan (Flu Mel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party. Freiburg: Universität.

Duque Afonso, J., Finke, J., Ngoya, M., Galimard, J.-E., Craddock, C., Raj, K., Bloor, A., Nicholson, E., Eder, M., Orchard, K., Valerius, T., Snowden, J.A., Tholouli, E., Crawley, C., Collin, M.P., Wilson, K.M.O., Gadisseur, A., Protheroe, R., Wagner-Drouet, E.-M., Savani, B.N., Spyridonidis, A., Ciceri, F., Nagler, A., Mohty, M., 2023. Comparison of fludarabine/melphalan (Flu Mel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party. Universität, Freiburg. https://doi.org/10.1038/s41409-023-02150-w

Duque Afonso, J., Finke, J., Ngoya, M., Galimard, J.-E., Craddock, C., Raj, K., Bloor, A., Nicholson, E., Eder, M., Orchard, K., Valerius, T., Snowden, J. A., Tholouli, E., Crawley, C., Collin, M. P., Wilson, K. M. O., Gadisseur, A., Protheroe, R., Wagner-Drouet, E.-M., Savani, B. N., Spyridonidis, A., Ciceri, F., Nagler, A., & Mohty, M. (ca. 2023). Comparison of fludarabine/melphalan (Flu Mel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party [Cd]. Universität. https://doi.org/10.1038/s41409-023-02150-w

Duque Afonso J, Finke J, Ngoya M, Galimard J-E, Craddock C, Raj K, Bloor A, Nicholson E, Eder M, Orchard K, Valerius T, Snowden JA, Tholouli E, Crawley C, Collin MP, Wilson KMO, Gadisseur A, Protheroe R, Wagner-Drouet E-M, Savani BN, Spyridonidis A, Ciceri F, Nagler A, Mohty M (2023) Comparison of fludarabine/melphalan (Flu Mel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party. Universität, Freiburg

Duque Afonso, Jesús/ Finke, Jürgen/ Ngoya, Maud/ Galimard, Jacques-Emmanuel/ Craddock, Charles/ Raj, Kavita/ Bloor, Adrian/ Nicholson, Emma/ Eder, Matthias/ Orchard, Kim/ Valerius, Thomas/ Snowden, John A./ Tholouli, Eleni/ Crawley, Charles/ Collin, Matthew P./ Wilson, Keith M. O./ Gadisseur, Alain/ Protheroe, Rachel/ Wagner-Drouet, Eva-Maria/ Savani, Bipin N./ Spyridonidis, Alexandros/ Ciceri, Fabio/ Nagler, Arnon/ Mohty, Mohamad, Comparison of fludarabine/melphalan (Flu Mel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party, Freiburg 2023.